Peer-reviewed veterinary case report
Survival times in dogs treated with mitotane or trilostane
By Barker, E N et al.·Published in Journal of veterinary internal medicine·2005·Department of Veterinary Clinical Studies, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism.
- Species:
- dog
Plain-English summary
A study looked at the survival times of 148 dogs diagnosed with pituitary-dependent hyperadrenocorticism, a condition that affects hormone levels. Most dogs were treated with a medication called trilostane, while a smaller group received mitotane. The results showed that both treatments had similar survival times, with dogs on trilostane living an average of about 662 days and those on mitotane about 708 days. Factors like age and weight at diagnosis were more important for survival than which medication was used. Overall, both treatments were effective, and the choice of medication did not significantly impact how long the dogs lived.
People also search for: dog Cushing's disease treatment · trilostane vs mitotane for dogs · dog survival time Cushing's disease
Abstract
The survival times of 148 dogs treated for pituitary-dependent hyperadrenocorticism were studied using clinical records from 3 UK veterinary centers between 1998 and 2003. Of these animals, 123 (83.1%) were treated with trilostane, while 25 (16.9%) were treated with mitotane. Treatment groups were compared using t-tests and analysis of variance (or their nonparametric equivalents) and chi-square tests. Survival data were analyzed using Kaplan-Meier survival plots and Cox proportional hazard methods. There was no significant difference between the population attributes from each center or between treatment groups. The median survival time for animals treated with trilostane was 662 days (range 8-1,971) and for mitotane it was 708 days (range 33-1,399). There were no significant differences between the survival times for animals treated with trilostane and those treated with mitotane. In the multivariable model (including drug, center, breed group, weight, diagnostic group, and age at diagnosis), only age at diagnosis and weight were significantly negatively associated with survival. Importantly, there was no significant effect of drug choice on survival.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16355673/